Managing bipolar disorder in the elderly: Defining the role of the newer agents

Drugs and Aging

Volumn 22, Issue 1, 2005, Pages 39-54

  Sajatovic, Martha ^a,d   Madhusoodanan, Subramoniam ^b,c   Coconcea, Nicoleta ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JOHN S EPISCOPAL HOSPITAL   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CIMETIDINE; CLOZAPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; LITHIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TERFENADINE; THIAZIDE DIURETIC AGENT; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; WARFARIN; ZIPRASIDONE; ZONISAMIDE;

AGE; AGED; AGING; AGRANULOCYTOSIS; ANOREXIA; ANTICHOLINERGIC EFFECT; ATAXIA; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BLOOD DYSCRASIA; BRAIN DISEASE; BRONCHITIS; CEREBELLUM DISEASE; CEREBROVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION LOSS; DIABETES MELLITUS; DISEASE EXACERBATION; DIZZINESS; DOSE CALCULATION; DROWSINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG USE; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; GERIATRIC CARE; HEADACHE; HUMAN; HYPERAMMONEMIA; HYPERAMMONEMIC ENCEPHALOPATHY; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPERTRIGLYCERIDEMIA; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INJURY; KIDNEY DISEASE; LIVER TOXICITY; MEDICAL LITERATURE; MEMORY DISORDER; METABOLIC DISORDER; NAUSEA; NEPHROLITHIASIS; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PUBLICATION; RASH; REVIEW; SCANTY HAIR; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STROKE; THOUGHT DISORDER; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREMOR; URINARY FREQUENCY; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN;

AGED; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG INTERACTIONS; HUMANS; LITHIUM;

EID: 13244295600     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200522010-00003     Document Type: Review

References (154)

1. Salzman C. Geriatric psychopharmacology. Ann Rev Med 1985; 36: 217-28
2. Naranjo CA, Herrmann NK, Mittmann N, et al. Recent advances in geriatric psychopharmacology. Drugs Aging 1995; 7: 184-202
3. Cassano GB, McElroy SL, Brady K, et al. Current issues in the identification and management of bipolar spectrum disorders in 'special populations'. J Affect Dis 2000; 59 Suppl 1: S69-79
4. Van Gerpen MW, Johnson JE, Winstead DK. Mania in the geriatric patient population. Am J Geriatr Psychiatry 1999; 7 (3): 188-202
5. Sajatovic M. Aging-related issues in bipolar disorder: a health services perspective. J Geriatr Psychiatry Neurol 2002; 15: 128-33
6. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Washington, DC: American Psychiatric Press, 2002
7. Russo P, Smith MW, Dirani R, et al. Pharmacotherapy patterns in the treatment of bipolar disorder. Bipolar Dis 2002; 4 (6): 366-77
8. Charney DS, Reynolds CF, Lebowitz BL, et al. Depression and bipolar support alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry 2003; 60 (7): 664-72
9. Shulman KI, Rochon P, Suykora K, et al. Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence. BMJ 2003; 326 (7396): 960-1
10. Goodwin FK, Jamison DR. Manic depressive illness. Oxford: Oxford University Press, 1999
11. McDonald WM, Tupler LA, Marsteller FA, et al. Hyper-intense lesions on magnetic resonance images in bipolar disorder. Biol Psychiatry 1999; 45: 965-71
12. Cassidy F, Carroll BJ. Vascular risk factors in late onset mania. Psychol Med 2002; 32: 359-62
13. Goldberg JR. Treatment guidelines: current and future management of bipolar disorder. J Clin Psychiatry 2000; 61 Suppl. 13: 12S-8S
14. Poolsup N, Li WPA, de Oliveira IR. Systemic overview of lithium treatment in acute mania. J Clin Pharmacol Ther 2000; 25 (2): 139-56
15. Ahmed Z, Anderson IM. Treatment of bipolar affective disorder in clinical practice. J Psychopharmacol 2001; 15 (1): 55-7
16. Levine J, Chengappa KN, Brar JS, et al. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Dis 2000; 2 (2): 120-30
17. Tueth MJ, Murphy TK, Evans DL. Special considerations: use of lithium in children, adolescents, and elderly populations. J Clin Psychiatry 1998; 590 Suppl. 6: 66S-73S
18. McDonald WM. Epidemiology, etiology, and treatment of geriatric mania. J Clin Psychiatry 2000; 61 Suppl. 13: 3S-11S
19. Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000; 16 (3): 165-77
20. Foster JR. Use of lithium in elderly psychiatric patients: a review of the literature. Lithium 1992; 3: 77-93
21. Chapron DJ. Comment on pharmacokinetics of lithium in the elderly [letter]. J Clin Psychopharmacol 1988; 8: 78
22. Shulman KI, Mackenzie S, Hardy B. The clinical use of lithium carbonate in old age: a review. Prog Neuropsychopharmacol Biol Psychiatry 1987; 11: 159-64
23. Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate [letter]. Am J Psychiatry 1989; 146 (2): 278
24. Noveske FG, Hahn KR, Glynn RJ. Possible toxicity of combined fluoxetine and lithium [letter]. Am J Psychiatry 1989; 146 (11): 1515
25. Stoudemire A, Hill CD, Lewison BJ, et al. Lithium intolerance in a medical-psychiatric population. Gen Hosp Psychiatry 1998; 20: 85-90
26. Jefferson JW, Griest JH, Ackerman DL, et al., editors. Lithium encyclopedia for clinical practice. 2nd ed. Washington, DC: American Psychiatric Press, 1987
27. Chen ST, Altshuler LL, Melnyk KA, et al. Efficacy of lithium vs valproate in the treatment of mania in the elderly, a retrospective study. J Clin Psychiatry 1999; 60: 181-6
28. Eastham JH, Jeste DV, Young RD. Assessment and treatment of bipolar disorder in the elderly. Drugs Aging 1998; 12 (3): 205-24
29. Fielding S, Kerr S, Godber C. Lithium in the over-65s: a dedicated monitoring service leads to better quality of treatment supervision. Int J Geriatr Psychiatry 1999; 14 (11): 985-7
30. Oshima A, Higuchi T. Treatment guidelines for geriatric mood disorders. Psychiatry Clin Neurosci 1999; 53 Suppl: 55-9
31. Evans DL, Byerly MJ, Greer RA. Secondary mania: diagnosis and treatment. J Clin Psychiatry 1995; 56 Suppl. 3: 26S-31S
32. McDonald WM, Nemeroff CB. The diagnosis and treatment of mania in the elderly. Bull Menninger Clin 1996; 60 (2): 175-96
33. Schneider AL, Wilcox CS. Divalproate augmentation in lithium-resistant rapid cycling mania in four geriatric patients. J Affect Dis 1998; 47: 201-5
34. Goldberg JF, Sacks MH, Kocsis JH. Low-dose lithium augmentation of divalproex in geriatric mania [letter]. J Clin Psychiatry 2000; 61 (4): 304
35. Willmore LJ. Choice and use of newer anticonvulsant drugs in older patients. Drugs Aging 2000; 17: 441-2
36. Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry 2004; 65 Suppl. 10: 28-35
37. Fuller M, Sajatovic M. Drug information handbook for psychiatry. 3rd ed. Cleveland (OH): Lexi-Comp Inc., 2002
38. Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Dis 1985; 8: 243-50
39. Kanba S, Yagi G, Kamijima K. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994; 189: 707-15
40. Sethi MA, Mehta R, Devanand DP. Gabapentin in geriatric mania. J Geriatr Psychiatry Neurol 2003; 16 (2): 117-20
41. Bernus I, Dickenson RG, Hooper WD, et al. Anticonvulsant therapy in aged patients: Clinical phamacokinetic considerations. Drugs Aging 1997; 10 (4): 278-89
42. Abbott Laboratories. Depakote® tablet product information: divalproex sodium delayed-release tablets. Abbott Park (IL): Abbott Laboratories, 2001
43. Porteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001; 9: 58-66
44. Tariot PN, Schneider LS, Mintzer JE, et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double blind, placebo-controlled trial. Curr Ther Res 2001; 62 (1): 51-67
45. Sanderson DR. Use of mood stabilizers by hospitalized geriatric patients with bipolar disorder. Psychiatr Serv 1998; 49 (9): 1145-7
46. Leppik IE. Issues in the treatment of epilepsy. Epilepsia 2001; 42 (4 Suppl.): 1S-6S
47. McFarland BH, Miller MR, Staumford E. Valproate use in the older manic patient. J Clin Psychiatry 1990; 51: 479-81
48. Puryear LJ, Kunik ME, Workman RI. Tolerability of divalproex sodium in elderly psychiatric patients with mixed diagnoses. J Geriatr Psychiatry Neurol 1995; 8 (4): 234-7
49. Mordecai DJ, Sheikh JI, Glick ED. Divalproex for the treatment of geriatric bipolar discord. Int J Geriatr Psychiatry 1999; 14: 494-6
50. Bowden CL, Janicak PG, Orsulak PJ, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996; 153: 765-70
51. Kando JC, Tohen M, Castillo J, et al. The use of valproate in an elderly population with affective symptoms. J Clin Psychiatry 1996; 57 (6): 238-40
52. Risinger RC, Risby ED, Risch SC. Safety and efficacy of divalproex sodium in elderly bipolar patients [letter]. J Clin Psychiatry 1994; 55 (5): 215
53. Bowden CL, Lawson DM, Cunningham M, et al. The role of divalproex in the treatment of bipolar disorder. Psychiatr Ann 2002; 32 (12): 742-50
54. Abbott FS, Kassam J, Orr JM, et al. The effect of aspirin on valproic acid metabolism. Clin Pharmacol Ther 1986; 40: 94-100
55. Wong SL, Cavanaugh J, Shi H, et al. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther 1996; 60: 48-53
56. Panjehshahin MR, Bowman CJ, Yates MS. Effect of valproic acid, its unsaturated metabolites and same structurally related fatty acids on the binding of warfarin and dansylsacrosine to human albumin. Biochem Pharmacol 1991; 41: 1227-33
57. Norton JW, Quarles E. Intravenous valproate in neuropsychiatry. Pharmacotherapy 2000; 20 (1): 88-92
58. Herbert PB, Nelson JC. Parenteral valproate for control of acute mania. Am J Psychiatry 2000; 157 (6): 1023-4
59. Regenold WT, Prasad M. Uses of intravenous valproate in geriatric psychiatry. Am J Geriatr Psychiatry 2001; 9 (3): 306-8
60. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-24
61. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400
62. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607-14
63. Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatr 2000; 12: 5-10
64. Leadbetter R, Messenheimer J, Bentley B, et al. Mood-stabilizing properties of lamotrigine: a review of data from controlled clinical trials. Psychiatr Ann 2002; 32 (12): 766-72
65. Robillard M, Conn DK. Lamotrigine use in geriatric patients with bipolar depression. Can J Psychiatry 2002; 47 (8): 767-70
66. Sajatovic M, Gyulai L, Calabrese JR, et al. Response to mood stabilizers in older patients with Bipolar I disorder. American Psychiatric Association Annual Meeting; 2004 May 1-6; New York
67. Rhodes LJ. Maintenance ECT replaced with lamotrigine. Am J Psychiatry 2000; 157 (12): 2058
68. Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 2002; 63 (8): 737-41
69. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46 (1): 152-76
70. Willmore LJ, Messenheimer JA. Adult experience with lamotrigine. J Child Neurol 1997; Suppl. 12: 16-8
71. Messenheimer JA. Lamotrigine. Epilepsia 1995; 36 Suppl. 2: 87-94
72. Posner J, Holdrich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1991; 1: 121-8
73. Calabrese JR, Shelton MD, Rapport DJ, et al. Bipolar disorders and the effectiveness of novel anticonvulsants. J Clin Psychiatry 2002; 63 (3 Suppl.): 5S-9S
74. Calabrese JR, Bowden CL, Sachs GS, et al., for the Lamictal 602 Study Group. A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79-88
75. Calabrese JR, Bowden CL, Sachs GS, et al., for the Lamictal 602 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000; 61: 841-50
76. Brodle MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy: the UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37: 81-7
77. Lamictal® (lamotrigine) [prescribing information]. Research Triangle Park (NC): ClaxoSmithKHne, 2004
78. Messenheimer JA. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci 1998; 25: S14-8
79. Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003; 44 Suppl. 4: 21-9
80. Beghi E, Perucca E. The management of epilepsy in the 1990s: acquisitions, uncertainties and priorities for future research. Drugs 1995; 49: 680-94
81. Beghi E. Carbamazepine: clinical efficacy and use in other neurological disorders. In: Levy R, Mattson R, Meldrum B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2002: 273-7
82. Battino D, Corci D, Rossini A, et al. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. Epilepsia 2003; 44 (7): 923-9
83. Greil W, Kleindiest N, Erazo N, et al. Differential response to lithium and carbamezepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998; 18 (6): 455-60
84. Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacol 2000; 150 (1): 15-23
85. Bowden CL. Acute and maintenance treatment with mood stabilizers. Int J Neuropsychopharmacol 2003; 6 (3): 269-75
86. Cates M, Powers R. Concomitant rash and blood dyscrasia in geriatric psychiatry patients treated with carbamazepine. Ann Pharmacother 1998; 32 (9): 884-7
87. Hirsch E, Schmitz B, Carreno M. Epilepsy, antiepileptic drugs (AEDs) and cognition. Acta Neurol Scan 2003; 108 Suppl.: 23-32
88. May T, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003; 42912: 1023-42
89. Van Heiningen PNM, Eve MD, Osterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991; 50 (4): 410-9
90. Kutluay E, McCague K, D'Souza J, et al. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 2003; 4 (2): 175-80
91. Cilli AS, Algun E. Oxcarbazepine-induced syndrome of inappropriate secretion of antidiuretic hormone [letter]. J Clin Psychiatry 2002; 63 (8): 742
92. Wong IC, Lhatoo SD. Adverse reactions to new anticonvulsant drugs. Drug Saf 2000; 23 (1): 35-56
93. Rose MA, Kam PCA. Gabapentin: pharmacology and its use in pain management. Anesthesia 2002; 57: 451-62
94. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group Bipolar Dis 2000; 2 (3): 249-55
95. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, editor. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine, 1993: 41-6
96. Vollmer KO, van Hodenberg AV, Kolle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittel-Forshung 1986; 36: 830-9
97. Fischer JH, Barr AN, Rogers SL, et al. Lack of serious toxicity following gabapentin overdose. Neurology 1994; 44: 982-3
98. Verma A, St Clair EW, Radtke RA. A case of sustained massive gabapentin overdose without serious side effects. Ther Drug Monit 1999; 21: 615-7
99. Busch JA, Radulovic LL, Bockbrader HN, et al. Effect of Maalox TC on single-dose pharmacokinetics of gabapentin capsules in healthy subjects. Pharm Res 1992; 9 Suppl.: S-315
100. Calabrese JR. A placebo-controlled study of topiramate in acute mania. European College of Neuropsychopharmacology (ECNP) Annual Meeting; 2000 Sep 9-13; Munich
101. Chengappa KNR, Gershon S, Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Dis 2001; 3: 215-342
102. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47: 1025-33
103. McIntyre R, Mancini D, McCann S, et al. Randomized, single-blind comparison of topiramate and bupropion as add-on therapy in bipolar depression [abstract]. Bipolar Dis 2001; 3 Suppl. 1: 47
104. Madhusoodanan S, Bogunovic O, Brenner R, et al. Use of topiramate as an adjunctive medication in elderly patients with treatment-resistant bipolar disorder. Am J Geriatr Psychiatry 2002; 10 (6): 759
105. Calabrese JR, Keck PE, McElroy SL, et al. A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol 2001; 21: 340-2
106. Chengappa KNR, Rathore D, Levine J, et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Dis 1999; 1: 42-53
107. Mehta S, Pryor F, Rowan AJ, et al. Tolerability and efficacy of topiramate in older patients [abstract no. 2.125]. Epilepsia 2001; 42 Suppl. 7: 143
108. Mattson R, Wang S, Water N. The effect of age on the tolerability of topiramate [abstract no. 2.255]. Epilepsia 2001; 42 Suppl. 7: 183
109. Rosenfield WE, PADS Investigator Group. Weight loss associated with topiramate, a new antiepileptic drug with potential psychoactive effects [poster]. Presented at XXIst Congress of the Collegium Internationale NeuroPsychopharmacologicum (CINP); 1998 Jul 15; Glasgow, 16068
110. Wasserstein AG, Rak I, Reige RA. Nephrolithiasis during treatment with topiramate [abstract]. Epilepsia 1995; 36 (S3): S153
111. Murata M, Horiuchi E, Kanazawa I. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res 2001; 41 (4): 397-9
112. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet 1996; 1: 29-46
113. Leppik IE, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993; 14 (2): 165-73
114. Sachs GS, Thase ME. Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry 2000; 48: 573-81
115. Sernyak M J, Griffin RA, Johnson RM, et al. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. Psychiatry 1994; 151: 133-5
116. Hunt N, Silverstone T. Tardive dyskinesia in bipolar affective disorder: a catchment area study. Int Clin Psychopharmacol 1991; 6: 45-50
117. Mukherjee S, Rosen AM, Caracci G, et al. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 1986; 43: 342-6
118. Hirschfield RMA. The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiatry 2003; 64 Suppl. 8: 15-21
119. Sajatovic M, Shelton M. Atypical antipsychotics in affective disorders. In: Czernansky J, Lauriello J, editors. Atypical antipsychotics: from bench to bedside. New York: Marcel-Dekker Inc., 2004
120. American Diabetes Association. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004; 27: 596-601
121. Meyer JM. A retrospective comparison of weight, lipid and glucose changes between risperidone and olanzapine treated inpatients: metabolic outcomes after one year. J Clin Psychiatry 2002; 63: 425-33
122. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factor in the United States. N Eng J Med 1993; 329: 162-7
123. Schulman RW, Singh A, Shulman KI. Treatment of elderly institutionalized bipolar patients with clozapine. Psychopharmacol Bull 1997; 33: 113-8
124. Sajatovic M, Ramirez LF, Carver D, et al. Clozapine therapy for older veterans. Psychiatric Serv 1998; 49: 340-4
125. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychosis associated with schizophrenia, schizoaffective disorder, bipolar disorder or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995; 56: 514-8
126. Madhusoodanan S, Suresh P, Brenner R, et al. Experience with the atypical antipsychotics risperidone and olanzapine in the elderly. Ann Clin Psychiatry 1999; 11 (3): 113-8
127. Bhana N, Spencer CM. Risperidone: a review of its use in the management of the behavioral and psychological symptoms of dementia. Drugs Aging 2000; 16 (6): 451-7
128. Risperidone (Risperdal®) [prescribing information]. Titusville (NJ): Janssen Pharmaceutic Products, 2003 Aug
129. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47 (6): 716-9
130. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. Can Med Assoc J. 2004; 167 (11): 1269-70
131. Wooltorton E. Risperidone (Risperdal): increased incidence of cerebrovascular events in dementia trials. Can Med Assoc J. 2004; 170 (9): 1395
132. Herrmann N, Mamdani M, Lanctot K. Atypical antipyschotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113-5
133. Jeste DV, Barak Y, Madhusoodanan S, et al. International multisite double-blind trial of the atypical antipsychotic risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psych 2003; 11 (6): 638-47
134. Davidson M, Harvey PD, Varvarcke J, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. Int J Geriatr Psychiatry 2000; 15: 506-14
135. Street J, Tollefson GD, Tohen M, et al. Olanzapine for psychotic conditions in the elderly. Psychiatr Ann 2000; 30 (3): 191-6
136. Bayer JL, Siegal A, Kennedy JS, et al. Olanzapine, divalproex, and placebo treatment, non-head to head comparisons of older adult acute mania. Institute on Psychiatric Services Annual Meeting; 2001 Oct 10-4; Orlando
137. Madhusoodanan S, Brenner R, Alcantre A. Clinical experience with quetiapine in elderly patients with psychotic disorders. J Geriatr Psychiatry Neurol 2000; 13: 28-32
138. Tariot PN, Salzman C, Yeung PP, et al. Long term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000; 22 (9): 1068-84
139. Yeung PR, Mintzer JE, Mullen JA, et al. Extrapyramidal symptoms in elderly outpatients treated with either quetiapine or risperidone [abstract no. 120]. Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco, 134
140. Jeste DV, Glazer WM, Morgenstern H, et al. Rarity of persistent tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly [abstract no. 104]. Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco, 96
141. Tariot PN, Salzman C, Yeung P, et al. Clinical improvement and tolerability is maintained long-term in elderly patients with psychotic disorders treated with quetiapine [abstract no. 120]. Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco, 98
142. McManus DQ, Arvanitis LA, Kowalcyk GG, et al. Quetiapine: a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999; 60 (5): 292-8
143. Zhong K, Tariot P, Minkwitz MC, et al. Quetiapine for the treatment of agitation in elderly institutionalized patients with dementia: a randomized, double-blind trial. The Ninth International Conference on Alzheimer's Disease and Related Disorders; 2004 Jul 22; Philadelphia
144. Sicuro R. Use of higher dose quetiapine in elderly patients: a chart review study [poster]. 16th Annual Meeting of the American Association for Geriatric Psychiatry; 2003 March 1-4; Oahu, 125
145. Alexopoulos GS, Streim J, Carpenter, et al. The expert consensus guideline series: using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65 Suppl. 2: 5-102
146. Pfizer Inc. Study Report of Ziprasidone Clinical Pharmacology protocol: F.D.A. Center for Drug Evaluation and Research Division of Cardiorenal Drug Products Consultation. Rockville (MD): US Food and Drug Administration, 2000
147. Berkowitz A. Experience with ziprasidone in elderly patients: case series. Second Annual Dementia Congress; 2003 Sep 12-4; Washington, DC
148. Etemad B. IM and oral ziprasidone in elderly patients with acute psychosis [abstract no. 213]. 55th Institute on Psychiatric Services, American Psychiatric Association; 2003 Oct 29-Nov 1; Boston: 181
149. Loebel A, Mackell J, Leaderer M, et al. Utilization of ziprasidone in elderly nursing facility residents [abstract no. 228]. 55th Institute on Psychiatric Services, American Psychiatric Association; 2003 Oct 29-Nov 1; Boston: 189
150. Geodon® [prescribing Information]. New York: Pfizer Inc, 2003
151. Abilify (aripiprazole) product information. Princeton (NJ): Bristol-Myers Squibb Co., 2002 Nov
152. DeDeyn P, Jeste DV, Auby P, et al. Aripiprazole in dementia of the Alzheimer's type. 16th Annual Meeting of the American Association for Geriatric Psychiatry; 2003 Mar 1-4, Honolulu
153. Goodwin GM, Consensus Group for the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17 (2): 149-73
154. McDonald WM, Thompson TR. Treatment of mania in dementia with electroconvulsive therapy. Psychopharmacol Bull 2001; 35 (2): 72-82